Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.15853 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs.
bioRxiv
February 2024
Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL.
The clinical use of interleukin-2 and -12 cytokines against cancer is limited by their narrow therapeutic windows due to on-target, off-tumor activation of immune cells when delivered systemically. Engineering IL-2 and IL-12 to bind to extracellular matrix collagen allows these cytokines to be retained within tumors after intralesional injection, overcoming these clinical safety challenges. While this approach has potentiated responses in syngeneic mouse tumors without toxicity, the complex tumor-immune interactions in human cancers are difficult to recapitulate in mouse models of cancer.
View Article and Find Full Text PDFVariable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
Acta Derm Venereol
June 2023
Department of Dermatology, Medical Centre - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Cutaneous squamous cell carcinoma (cSCC) is a major complication of recessive dystrophic epidermolysis bullosa (RDEB) that has high morbidity and mortality rates and unmet therapeutic needs. The aim of this study was to evaluate the molecular pattern of cSCC and the clinical course of immunotherapy in 2 RDEB patients with multiple advanced cSCC. Clinical course and disease staging were evaluated retrospectively.
View Article and Find Full Text PDFInvestigation of Adverse Reactions in Tattooed Skin through Histological and Chemical Analysis.
Dermatology
October 2023
Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Article Synopsis
- The increase in people with tattoos has led to a rise in adverse skin reactions, primarily due to unidentified substances in tattoo colorants that can cause allergies or granulomatous reactions.
- A study involving ten patients with adverse reactions included skin biopsies and extensive testing of tattoo colorants using various scientific methods to identify the triggers of these skin issues.
- Results showed varied skin reactions linked mainly to red tattoos, and while some substances in the colorants were identified, treatments such as topical steroids proved effective for seven patients in achieving remission from their symptoms.
Vaccination Following Intratumoral Injection of IL2 and Poly-l-lysine/Iron Oxide/CpG Nanoparticles to a Radiated Tumor Site.
ACS Nano
June 2023
Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
The vaccine effect of radiation therapy (RT) has been shown to be limited in both preclinical and clinical settings, possibly due to the inadequacy of RT alone to stimulate vaccination in immunologically "cold" tumor microenvironments (TMEs) and the mixed effects of RT in promoting tumor infiltration of both effector and suppressor immune cells. To address these limitations, we combined intratumoral injection of the radiated site with IL2 and a multifunctional nanoparticle (PIC). The local injection of these agents produced a cooperative effect that favorably immunomodulated the irradiated TME, enhancing the activation of tumor-infiltrating T cells and improving systemic anti-tumor T cell immunity.
View Article and Find Full Text PDFAbscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG.
Front Oncol
April 2023
Division of General and Gastrointestinal Surgery, Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Cutaneous melanoma is relatively common with increasing incidence and significant mortality. While the mainstay of therapy is surgical, patients with stage III and IV disease fare poorer than those with early-stage disease and often benefit from adjuvant therapies. While systemic immunotherapy has changed the landscape of melanoma treatment, for some patients systemic toxicities related to these treatments prohibit successful administration or completion of therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!